Breakthrough cancer trial offers hope for pancreatic cancer patients
Local 12 highlights KRAS inhibitor trial enrolling patients at Cancer Center
Local 12 highlighted University of Cincinnati Cancer Center researcher Davendra Sohal and patient Ron Solomon, who is enrolled in a pancreatic cancer trial targeting a genetic mutation called KRAS.
Solomon's pancreatic cancer, which had spread to his liver, was not responding to standard therapy, but testing found the cancer had the specific KRAS gene mutation.
"KRAS is a gene that is an on-switch in many of these cancers," said Sohal, MD, associate director for clinical research at the Cancer Center and professor of internal medicine in UC’s College of Medicine. "Basically, it turns the cancer cells on, and these drugs try to turn that switch off, so the cancer cells stop growing. They essentially go to sleep, even if they are not killed."
The new KRAS inhibitor drugs like the one being tested in this trial provide targeted therapy in contrast to traditional chemotherapy drugs.
"These are now the most promising drugs in pancreatic and other cancers such as lung cancer and colon cancer," Sohal said.
The new drugs are given in pill form and taken daily, and Solomon is monitored for side effects each week. He said he's been encouraged that he has not felt sick from the new medication.
"Throughout all of this since the very beginning, I've been very, very fortunate, and very grateful, and hopeful," Solomon said.
Read or watch the Local 12 story.
Featured image at top of Davendra Sohal. Photo/UC Health.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.